SG11201913175TA - Anti-b-cell maturation antigen chimeric antigen receptors with human domains - Google Patents
Anti-b-cell maturation antigen chimeric antigen receptors with human domainsInfo
- Publication number
- SG11201913175TA SG11201913175TA SG11201913175TA SG11201913175TA SG11201913175TA SG 11201913175T A SG11201913175T A SG 11201913175TA SG 11201913175T A SG11201913175T A SG 11201913175TA SG 11201913175T A SG11201913175T A SG 11201913175TA SG 11201913175T A SG11201913175T A SG 11201913175TA
- Authority
- SG
- Singapore
- Prior art keywords
- cell maturation
- human domains
- antigen
- receptors
- chimeric antigen
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 230000035800 maturation Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762527556P | 2017-06-30 | 2017-06-30 | |
PCT/US2018/039917 WO2019006072A1 (en) | 2017-06-30 | 2018-06-28 | Anti-b-cell maturation antigen chimeric antigen receptors with human domains |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201913175TA true SG11201913175TA (en) | 2020-01-30 |
Family
ID=63350586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201913175TA SG11201913175TA (en) | 2017-06-30 | 2018-06-28 | Anti-b-cell maturation antigen chimeric antigen receptors with human domains |
Country Status (11)
Country | Link |
---|---|
US (2) | US20200138865A1 (en) |
EP (2) | EP3645568B1 (en) |
JP (2) | JP7288405B2 (en) |
KR (1) | KR20200049757A (en) |
CN (1) | CN111094345B (en) |
AU (1) | AU2018291128A1 (en) |
CA (1) | CA3068444A1 (en) |
ES (1) | ES2928296T3 (en) |
IL (1) | IL271597B2 (en) |
SG (1) | SG11201913175TA (en) |
WO (1) | WO2019006072A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2766608C2 (en) | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Chimeric antigen receptors targeted b-cell maturation antigen |
KR20190053835A (en) | 2016-06-21 | 2019-05-20 | 테네오바이오, 인코포레이티드 | CD3 binding antibody |
DK4050034T3 (en) | 2016-09-14 | 2024-06-03 | Teneoone Inc | CD3-BINDING ANTIBODIES |
IL271194B1 (en) | 2017-06-20 | 2024-06-01 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
BR112019026803A2 (en) | 2017-06-20 | 2020-06-30 | Teneoone, Inc. | anti-bcma heavy chain antibodies only |
MX2020006689A (en) * | 2017-12-20 | 2020-11-06 | Poseida Therapeutics Inc | Vcar compositions and methods for use. |
EA202091557A1 (en) | 2017-12-22 | 2020-11-18 | Тенеобио, Инк. | ANTIBODIES CONTAINING ONLY HEAVY CHAINS THAT BIND CD22 |
AU2020240132A1 (en) | 2019-03-21 | 2021-09-16 | Regeneron Pharmaceuticals, Inc. | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy |
TW202108628A (en) | 2019-06-14 | 2021-03-01 | 美商泰尼歐生物公司 | Multispecific heavy chain antibodies binding to cd22 and cd3 |
US20230203161A1 (en) | 2020-04-29 | 2023-06-29 | Teneobio, Inc | Multispecific heavy chain antibodies with modified heavy chain constant regions |
TW202330622A (en) | 2020-04-29 | 2023-08-01 | 美商泰尼歐生物公司 | Multispecific heavy chain antibodies with modified heavy chain constant regions |
CA3189297A1 (en) | 2020-06-30 | 2022-01-06 | Nathan Trinklein | Multi-specific antibodies binding to bcma |
JP2024501971A (en) | 2020-12-31 | 2024-01-17 | サナ バイオテクノロジー,インコーポレイテッド | Methods and compositions for modulating CAR-T activity |
TW202242121A (en) | 2021-01-11 | 2022-11-01 | 美商薩那生物科技公司 | Use of cd8-targeted viral vectors |
BR112023024231A2 (en) | 2021-05-19 | 2024-01-30 | Sana Biotechnology Inc | HYPOIMMUNOGENIC RHD NEGATIVE PRIMARY T CELLS |
AU2022283291A1 (en) | 2021-05-27 | 2023-11-02 | Sana Biotechnology, Inc. | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
EP4364746A1 (en) * | 2021-07-01 | 2024-05-08 | Ningbo T-MAXIMUM Biopharmaceuticals Co., Ltd. | UNIVERSAL CAR-T CELL TARGETING IL13Ra2, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF |
AU2022309875A1 (en) | 2021-07-14 | 2024-01-25 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
KR20240053673A (en) | 2021-08-11 | 2024-04-24 | 사나 바이오테크놀로지, 인크. | Inducible system for altering gene expression in hypoimmunogenic cells |
WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
WO2023115039A2 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
TW202342757A (en) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | Modified paramyxoviridae attachment glycoproteins |
CA3241438A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2766608C2 (en) * | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Chimeric antigen receptors targeted b-cell maturation antigen |
ES2857226T3 (en) * | 2014-03-15 | 2021-09-28 | Novartis Ag | Regulable chimeric antigen receptor |
SG10201810507WA (en) * | 2014-06-06 | 2018-12-28 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
CN105384825B (en) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
IL271194B1 (en) * | 2017-06-20 | 2024-06-01 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
-
2018
- 2018-06-28 CN CN201880044208.XA patent/CN111094345B/en active Active
- 2018-06-28 JP JP2019572798A patent/JP7288405B2/en active Active
- 2018-06-28 ES ES18759189T patent/ES2928296T3/en active Active
- 2018-06-28 EP EP18759189.6A patent/EP3645568B1/en active Active
- 2018-06-28 WO PCT/US2018/039917 patent/WO2019006072A1/en active Application Filing
- 2018-06-28 EP EP22187063.7A patent/EP4159762A1/en active Pending
- 2018-06-28 CA CA3068444A patent/CA3068444A1/en active Pending
- 2018-06-28 KR KR1020207002752A patent/KR20200049757A/en not_active Application Discontinuation
- 2018-06-28 US US16/626,991 patent/US20200138865A1/en not_active Abandoned
- 2018-06-28 AU AU2018291128A patent/AU2018291128A1/en active Pending
- 2018-06-28 SG SG11201913175TA patent/SG11201913175TA/en unknown
- 2018-06-28 IL IL271597A patent/IL271597B2/en unknown
-
2023
- 2023-02-13 JP JP2023020373A patent/JP2023071729A/en active Pending
- 2023-11-30 US US18/524,799 patent/US20240091264A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018291128A1 (en) | 2020-01-23 |
CA3068444A1 (en) | 2019-01-03 |
KR20200049757A (en) | 2020-05-08 |
EP3645568A1 (en) | 2020-05-06 |
CN111094345A (en) | 2020-05-01 |
US20200138865A1 (en) | 2020-05-07 |
JP2020529841A (en) | 2020-10-15 |
EP4159762A1 (en) | 2023-04-05 |
IL271597B1 (en) | 2023-11-01 |
CN111094345B (en) | 2023-10-27 |
IL271597A (en) | 2020-02-27 |
JP2023071729A (en) | 2023-05-23 |
ES2928296T3 (en) | 2022-11-16 |
WO2019006072A1 (en) | 2019-01-03 |
IL271597B2 (en) | 2024-03-01 |
JP7288405B2 (en) | 2023-06-07 |
US20240091264A1 (en) | 2024-03-21 |
EP3645568B1 (en) | 2022-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL271597A (en) | Anti-b-cell maturation antigen chimeric antigen receptors with human domains | |
IL275619A (en) | Enhanced chimeric antigen receptors and uses thereof | |
IL277078A (en) | Anti-cd33 chimeric antigen receptors and their uses | |
IL263626A (en) | Chimeric antigen receptors and methods for use | |
ZA201800703B (en) | Chimeric antigen receptors based on single¿domain antibodies and methods of use thereof | |
IL262041A (en) | Chimeric receptors and methods of use thereof | |
EP3658163A4 (en) | Enhanced chimeric antigen receptors and use thereof | |
HK1249405A1 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
IL257138A (en) | Chimeric antigen receptors with integrated controllable functions | |
IL255336A0 (en) | Chimeric antigen receptors and methods of their use | |
IL280029A (en) | Ror-1 specific chimeric antigen receptors and uses thereof | |
IL274147A (en) | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen | |
HK1252854A1 (en) | Kappa myeloma antigen chimeric antigen receptors and uses thereof | |
SG11201701297WA (en) | Antibodies and chimeric antigen receptors specific for cd19 | |
IL265219A (en) | Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof | |
IL280033A (en) | Uses of anti-bcma chimeric antigen receptors | |
IL265438A (en) | Chimeric antigen receptors and compositions and methods of use thereof | |
ZA202005837B (en) | Cd83-binding chimeric antigen receptors | |
IL278976A (en) | Muc16 specific chimeric antigen receptors and uses thereof | |
IL286984A (en) | Humanized anti-dll3 chimeric antigen receptors and uses thereof | |
IL287487A (en) | Rituximab-resistant chimeric antigen receptors and uses thereof | |
GB2585607B (en) | Chimeric antigen receptor and application thereof |